Gilead’s Q3 Earnings Drop Amid 6.8% Revenue Growth: What It Means for Investors
Gilead Sciences sees Q3 earnings drop yet revenue climbs 6.8% to $8.3B, highlighting resilience in HIV, liver, and heart therapies amid market swings.
2 minutes to read
GILEAD SCIENCES INC